|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Weinberg RA: How cancer arises. Sci Am.
275:62–70. 1996. View Article : Google Scholar
|
|
3
|
Weigelt B, Peterse JL and van’t Veer LJ:
Breast cancer metastasis: markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paridaens R, Biganzoli L, Bruning P, Klijn
JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A,
Sylvester R, Awada A, Wildiers J and Piccart M: Paclitaxel versus
doxorubicin as first-line single-agent chemotherapy for metastatic
breast cancer: a European Organization for Research and Treatment
of cancer randomized study with cross-over. J Clin Oncol.
18:724–733. 2000.PubMed/NCBI
|
|
5
|
Garcia-Carbonero R and Supko JG: Current
perspectives on the clinical experience, pharmacology, and
continued development of the camptothecins. Clin Cancer Res.
8:641–661. 2002.PubMed/NCBI
|
|
6
|
Galano G, Caputo M, Tecce MF and Capasso
A: Efficacy and tolerability of vinorelbine in the cancer therapy.
Curr Drug Saf. 6:185–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma
K, Yokoo Y and Kamiya T: Capsaicin-like anti-obese activities of
evodiamine from fruits of Evodia rutaecarpa, a vanilloid
receptor agonist. Planta Med. 67:628–633. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dai JP, Li WZ, Zhao XF, Wang GF, Yang JC,
Zhang L, Chen XX, Xu YX and Li KS: A drug screening method based on
the autophagy pathway and studies of the mechanism of evodiamine
against influenza A virus. PLoS One. 7:e427062012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rang WQ, Du YH, Hu CP, Ye F, Xu KP, Peng
J, Deng HW and Li YJ: Protective effects of evodiamine on
myocardial ischemia-reperfusion injury in rats. Planta Med.
70:1140–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin H, Tsai SC, Chen JJ, Chiao YC, Wang
SW, Wang GJ, Chen CF and Wang PS: Effects of evodiamine on the
secretion of testosterone in rat testicular interstitial cells.
Metabolism. 48:1532–1535. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang C, Fan X, Xu X, Yang X, Wang X and
Liang HP: Evodiamine induces caspase-dependent apoptosis and S
phase arrest in human colon lovo cells. Anticancer Drugs.
21:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kan SF, Huang WJ, Lin LC and Wang PS:
Inhibitory effects of evodiamine on the growth of human prostate
cancer cell line LNCaP. Int J Cancer. 110:641–651. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen MC, Yu CH, Wang SW, Pu HF, Kan SF,
Lin LC, Chi CW, Ho LL, Lee CH and Wang PS: Anti-proliferative
effects of evodiamine on human thyroid cancer cell line ARO. J Cell
Biochem. 110:1495–1503. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang ZG, Chen AQ and Liu B:
Antiproliferation and apoptosis induced by evodiamine in human
colorectal carcinoma cells (COLO-205). Chem Biodivers. 6:924–933.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ogasawara M, Matsubara T and Suzuki H:
Screening of natural compounds for Inhibitory activity on colon
cancer cell migration. Biol Pharm Bull. 24:720–723. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogasawara M, Matsunaga T, Takahashi S,
Saiki I and Suzuki H: Anti-invasive and metastatic activities of
evodiamine. Biol Pharm Bull. 25:1491–1493. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ogasawara M, Matsubara T and Suzuki H:
Inhibitory effects of evodiamine on in vitro invasion and
experimental lung metastasis of murine colon cancer cells. Biol
Pharm Bull. 24:917–920. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takada Y, Kobayashi Y and Aggarwal BB:
Evodiamine abolishes constitutive and inducible NF-κB activation by
inhibiting IκBα kinase activation, thereby suppressing
NF-κB-regulated antiapoptotic and metastatic gene expression,
up-regulating apoptosis, and inhibiting invasion. J Biol Chem.
280:17203–17212. 2005.PubMed/NCBI
|
|
19
|
Zhou WH, Du MR, Dong L, Zhu XY, Yang JY,
He YY and Li DJ: Cyclosporin A increases expression of matrix
metalloproteinase 9 and 2 and invasiveness in vitro of the
first-trimester human trophoblast cells via the mitogen-activated
protein kinase pathway. Hum Reprod. 22:2743–2750. 2007. View Article : Google Scholar
|
|
20
|
Köhrmann A, Kammerer U, Kapp M, Dietl J
and Anacker J: Expression of matrix metalloproteinases (MMPs) in
primary human breast cancer and breast cancer cell lines: new
findings and review of the literature. BMC Cancer.
9:1882009.PubMed/NCBI
|
|
21
|
Ulisse S, Baldini E, Sorrenti S and
D’Armiento M: The urokinase plasminogen activator system: a target
for anti-cancer therapy. Curr Cancer Drug Targets. 9:32–71. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han B, Nakamura M, Mori I, Nakamura Y and
Kakudo K: Urokinase-type plasminogen activator system and breast
cancer (Review). Oncol Rep. 14:105–112. 2005.PubMed/NCBI
|
|
23
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hunter T and Pines J: Cyclins and cancer.
II: cyclin D and CDK inhibitors come of age. Cell. 79:573–582.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Zhang QH, Wu LJ, Tashiro S,
Onodera S and Ikejima T: Atypical apoptosis in L929 cells induced
by evodiamine isolated from Evodia rutaecarpa. J Asian Nat
Prod Res. 6:19–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Korsmeyer SJ, Shutter JR, Veis DJ, Merry
DE and Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an
anti-oxidant pathway and cell death. Semin Cancer Biol. 4:327–332.
1993.PubMed/NCBI
|
|
27
|
Wu GS: Role of mitogen-activated protein
kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev.
26:579–585. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reddy KB, Nabha SM and Atanaskova N: Role
of MAP kinase in tumor progression and invasion. Cancer Metastasis
Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seddighzadeh M, Zhou JN, Kronenwett U,
Shoshan MC, Auer G, Sten-Linder M, Wiman B and Linder S: ERK
signalling in metastatic human MDA-MB-231 breast carcinoma cells is
adapted to obtain high urokinase expression and rapid cell
proliferation. Clin Exp Metastasis. 17:649–654. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
You J, Mi D, Zhou X, Qiao L, Zhang H,
Zhang X and Ye L: A positive feedback between activated
extracellularly regulated kinase and cyclooxygenase/lipoxygenase
maintains proliferation and migration of breast cancer cells.
Endocrinology. 150:1607–1617. 2009. View Article : Google Scholar
|
|
32
|
Li T, Feng Z, Jia S, Wang W, Du Z, Chen N
and Chen Z: Daintain/AIF-1 promotes breast cancer cell migration by
up-regulated TNF-α via activate p38 MAPK signaling pathway. Breast
Cancer Res Treat. 131:891–898. 2012.PubMed/NCBI
|
|
33
|
Xia Z, Dickens M, Raingeaud J, Davis RJ
and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases
on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Zhang QH, Wu LJ, Shin-Ichi
Tashiro, Satoshi O and Takashi I: Regulation of ERK MAPK in
evodiamine-induced A375-S2 cell death. Chin J Pathophysiol.
20:2175–2179. 2004.
|
|
35
|
Zelivianski S, Spellman M, Kellerman M,
Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL,
Hauke R and Lin MF: ERK inhibitor PD98059 enhances
docetaxel-induced apoptosis of androgen-independent human prostate
cancer cells. Int J Cancer. 107:478–485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fiddes RJ, Janes PW, Sivertsen SP,
Sutherland RL, Musgrove EA and Daly RJ: Inhibition of the MAP
kinase cascade blocks heregulin-induced cell cycle progression in
T-47D human breast cancer cells. Oncogene. 16:2803–2813. 1998.
View Article : Google Scholar
|
|
37
|
Boldt S, Weidle UH and Kolch W: The role
of MAPK pathways in the action of chemotherapeutic drugs.
Carcinogenesis. 23:1831–1838. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Porras A, Zuluaga S, Black E, Valladares
A, Alvarez AM, Ambrosino C, Benito M and Nebreda AR: P38α
mitogen-activated protein kinase sensitizes cells to apoptosis
induced by different stimuli. Mol Biol Cell. 15:922–933. 2004.
|
